Tokyo Tape
Sign in
← ASKA Pharmaceutical Holdings

Quarterly report · Q3

4886.TEDINET S100SSGE
Period2023-04-01 → 2023-12-31
Filed2024-02-09
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥48.8bn2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥60.5bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥47.3bn2022-04-01 → 2022-12-31Cons.Net sales
Operating income¥5.5bn2023-04-01 → 2023-12-31Cons.Operating income
Operating income¥5.0bn2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income¥5.6bn2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥5.2bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥5.2bn2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥8.5bn2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥5.4bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)¥6.5bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.2bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥4.2bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income¥6.5bn2023-04-01 → 2023-12-31Cons.Profit loss
Net income¥4.2bn2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥94.9bnat 2023-12-31Cons.Assets
Total assets¥87.1bnat 2023-03-31Cons.Assets
Total assets¥90.8bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥34.5bnat 2023-12-31Cons.Liabilities
Total liabilities¥32.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥60.4bnat 2023-12-31Cons.Net assets
Net assets / equity¥54.5bnat 2023-03-31Cons.Net assets
Net assets / equity¥54.1bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥17.5bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥14.5bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥228.132023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥82.192023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥150.082022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥148.192022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥64.972022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio63.7%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio59.6%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 34
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-12-31¥166m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-12-31¥124m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-12-31¥41m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-12-31−¥103m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥41m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥41m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥903m
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥5.1bn
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥5.1bn
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥186m
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥43.6bn
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥43.6bn
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥6.3bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-12-31¥48.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-12-31¥48.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-12-31¥41m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-12-31¥6.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-12-31¥196m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-12-31¥155m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-12-31¥41m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-12-31−¥26m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥41m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥41m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥767m
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥5.2bn
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥5.2bn
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥417m
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥41.9bn
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥41.9bn
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥5.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥47.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥47.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥41m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥5.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 328
ItemContextValueUnit
Current liabilitiesPrior1YearInstant17650000000JPY
Current liabilitiesCurrentQuarterInstant21520000000JPY
Long term loans payablePrior1YearInstant9185000000JPY
Long term loans payableCurrentQuarterInstant6925000000JPY
Net defined benefit liabilityPrior1YearInstant5433000000JPY
Net defined benefit liabilityCurrentQuarterInstant5680000000JPY
Other nclPrior1YearInstant335000000JPY
Other nclCurrentQuarterInstant339000000JPY
Noncurrent liabilitiesPrior1YearInstant14954000000JPY
Noncurrent liabilitiesCurrentQuarterInstant12945000000JPY
LiabilitiesPrior1YearInstant32604000000JPY
LiabilitiesCurrentQuarterInstant34465000000JPY
Capital stockPrior1YearInstant1197000000JPY
Capital stockCurrentQuarterInstant1197000000JPY
Capital surplusPrior1YearInstant1847000000JPY
Capital surplusCurrentQuarterInstant1848000000JPY
Retained earningsPrior1YearInstant49619000000JPY
Retained earningsCurrentQuarterInstant55284000000JPY
Treasury stockPrior1YearInstant-3350000000JPY
Treasury stockCurrentQuarterInstant-3287000000JPY
Shareholders equityPrior1YearInstant49315000000JPY
Shareholders equityCurrentQuarterInstant55043000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant4590000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant4458000000JPY
Foreign currency translation adjustmentPrior1YearInstant405000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant691000000JPY
Remeasurements of defined benefit plansPrior1YearInstant222000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant198000000JPY
Valuation and translation adjustmentsPrior1YearInstant5218000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant5348000000JPY
Net assetsPrior1YearInstant54533000000JPY
Net assetsCurrentQuarterInstant60391000000JPY
Liabilities and net assetsPrior1YearInstant87138000000JPY
Liabilities and net assetsCurrentQuarterInstant94857000000JPY
Net salesPrior1YTDDuration47259000000JPY
Net salesCurrentYTDDuration48824000000JPY
Cost of salesPrior1YTDDuration24893000000JPY
Cost of salesCurrentYTDDuration25193000000JPY
Gross profitPrior1YTDDuration22366000000JPY
Gross profitCurrentYTDDuration23631000000JPY
Selling general and administrative expensesPrior1YTDDuration17324000000JPY
Selling general and administrative expensesCurrentYTDDuration18104000000JPY
Operating incomePrior1YTDDuration5041000000JPY
Operating incomeCurrentYTDDuration5526000000JPY
Interest income noiPrior1YTDDuration0JPY
Interest income noiCurrentYTDDuration3000000JPY
Dividends income noiPrior1YTDDuration331000000JPY
Dividends income noiCurrentYTDDuration321000000JPY
Other noiPrior1YTDDuration70000000JPY
Other noiCurrentYTDDuration53000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass